重症精准医学试验中蛋白质定量平台的范围综述
该范围综述检索了PubMed、Embase和Espacenet,纳入228篇来源(211篇出版物、14篇专利、3篇公司通讯),提取了256条出版物来源的设备记录,代表来自34家制造商的74种不同自动化设备型号。最常出现的设备为Ella(n=48)、LUMIPULSE G1200(n=25)、LUMIPULSE G600II(n=17)、cobas e 411(n=13)和Simoa HD-X(n=12)。出版物中仅8种设备具有多重检测能力,公司通讯另补充2种。炎症和神经生物标志物为主,最常报道的炎症标志物为降钙素原(n=36)、IL-6(n=35)、TNF-α(n=22)和IL-10(n=14),神经标志物为神经丝轻链(n=34)、p-tau217(n=31)、Aβ42(n=29)、Aβ40(n=27)和p-tau181(n=27)。结论认为自动化平台众多但多重能力有限,需要更标准化的设备级报告以支持平台选择。
要点
- 本综述识别了74种自动化蛋白质定量设备型号(来自34家制造商),可用于血液、血清或血浆中人蛋白质生物标志物的定量测量。
- 出版物中最常报道的设备为Ella(n=48)、LUMIPULSE G1200(n=25)、LUMIPULSE G600II(n=17)、cobas e 411(n=13)和Simoa HD-X(n=12)。
- 出版物中仅8种设备具有多重检测能力,公司通讯另补充2种多重检测平台。
- 最常报道的炎症生物标志物为降钙素原(n=36)、IL-6(n=35)、TNF-α(n=22)和IL-10(n=14)。
- 最常报道的神经生物标志物为神经丝轻链(n=34)、p-tau217(n=31)、Aβ42(n=29)、Aβ40(n=27)和p-tau181(n=27)。
适用人群与场景
- 计划开展生物标志物驱动的精准医学试验的重症医学研究者;设备需满足对血液、血清或血浆中人蛋白质生物标志物进行定量测量的预设自动化定义。
诊断标准与关键阈值
- 纳入标准:出版物报告、专利报告或公司通讯,描述符合预设自动化定义的市售平台,可定量测量一种或多种人血液、血清或血浆蛋白质生物标志物。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 范围综述纳入228篇来源(211篇出版物、14篇专利、3篇公司通讯),出版物贡献256条设备记录,代表74种自动化设备型号(34家制造商)。
- 最常报道的设备为Ella(n=48)、LUMIPULSE G1200(n=25)、LUMIPULSE G600II(n=17)、cobas e 411(n=13)、Simoa HD-X(n=12)。
- 出版物中8种设备具有多重检测能力,公司通讯另识别2种多重检测平台。
- 最常报道的炎症标志物为降钙素原(n=36)、IL-6(n=35)、TNF-α(n=22)、IL-10(n=14)。
- 最常报道的神经标志物为神经丝轻链(n=34)、p-tau217(n=31)、Aβ42(n=29)、Aβ40(n=27)、p-tau181(n=27)。
证据类型、等级与局限
- 研究类型:范围综述;检索PubMed、Embase和Espacenet,并纳入相关公司通讯;局限包括多重检测能力有限,且设备级报告需要更标准化。
对床旁实践的改变
- 为生物标志物驱动的重症精准医学试验选择平台时,可参考本综述列出的自动化设备型号及已报道的检测标志物,但需注意多重检测能力有限。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Among precision medicine approaches in critical care, protein biomarker quantification offers a timely and reproducible route to patient subtyping, but the landscape of automated platforms suitable for near-patient deployment remains unclear. This review aimed to identify available automated platforms for quantitative measurement of human protein biomarkers in blood, serum, or plasma, in order to support planning for precision medicine trials.
DATA SOURCES: PubMed, Embase, and Espacenet were searched for eligible sources. Relevant company correspondence was also included where available.
STUDY SELECTION: Publication reports, patent reports, and company correspondence were eligible if they described commercially available platforms meeting a prespecified definition of automation for quantitative measurement of one or more human protein biomarkers in blood, serum, or plasma.
DATA EXTRACTION: Data were extracted on device model, manufacturer, and analytes measured. Eligible devices were extracted as separate device records, including multiple devices reported within a single source.
DATA SYNTHESIS: Overall, 228 sources were included, comprising 211 publication reports, 14 patent reports, and three company correspondence reports. Publications contributed 256 publication-derived device records representing 74 distinct automated device models from 34 manufacturers. The most frequently represented devices were Ella (n = 48), LUMIPULSE G1200 (n = 25), LUMIPULSE G600II (n = 17), cobas e 411 (n = 13), and Simoa HD-X (n = 12). Multiplex capability was identified for eight devices in included publications, with two additional multiplex-capable platforms identified through company correspondence. Across publication-derived device records, inflammatory and neurologic biomarkers predominated. The most frequently reported inflammatory biomarkers were procalcitonin (n = 36), interleukin (IL)-6 (n = 35), tumor necrosis factor (TNF)-α (n = 22), and IL-10 (n = 14). The most frequently reported neurologic biomarkers were neurofilament light chain (n = 34), p-tau217 (n = 31), Aβ42 (n = 29), Aβ40 (n = 27), and p-tau181 (n = 27).
CONCLUSIONS: Automated platforms for quantitative protein biomarker measurement span numerous devices and manufacturers, but multiplex capability remains limited. More standardized device-level reporting would strengthen platform selection for biomarker-enabled trials and future clinical implementation.
参考来源
- McMullan RR, Campbell D, Rea A, et al. Protein Quantification Platforms For Use In Critical Care Precision Medicine Trials: A Scoping Review. Crit Care Explor. 2026. PMID: 42695277. doi:10.1097/CCE.0000000000001477
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。